生物制药公司Biomea Fusion近日发布了其针对1型糖尿病研发的II期临床研究Covalent-112的52周积极结果。数据显示,患者在完成12周Icovamenib治疗后,展现出C肽指标的显著提升,且疗效表现出持久性特征。
生物制药公司Biomea Fusion近日发布了其针对1型糖尿病研发的II期临床研究Covalent-112的52周积极结果。数据显示,患者在完成12周Icovamenib治疗后,展现出C肽指标的显著提升,且疗效表现出持久性特征。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.